Author:
Lebwohl Mark,Yeilding Newman,Szapary Philippe,Wang Yuhua,Li Shu,Zhu Yaowei,Reich Kristian,Langley Richard G.,Papp Kim A.
Reference20 articles.
1. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1);Leonardi;Lancet,2008
2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2);Papp;Lancet,2008
3. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial;Menter;J Am Acad Dermatol,2008
4. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension;van de Kerkhof;Br J Dermatol,2008
5. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis;Menter;J Am Acad Dermatol,2007
Cited by
116 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献